MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
IPO Year: 2018
Exchange: NASDAQ
Website: morphosys.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/14/2024 | Overweight → Equal Weight | Wells Fargo | |
| 1/16/2024 | $9.19 → $10.40 | Overweight → Equal-Weight | Morgan Stanley |
| 10/13/2023 | $3.70 → $9.19 | Underweight → Overweight | Morgan Stanley |
| 9/15/2023 | $3.50 → $9.25 | Sell → Neutral | Goldman |
| 7/17/2023 | Sell → Hold | Deutsche Bank | |
| 6/16/2023 | $3.30 → $10.00 | Underweight → Overweight | JP Morgan |
| 6/16/2023 | $17.00 | Overweight | Wells Fargo |
| 5/31/2023 | Buy | UBS | |
| 1/6/2023 | Equal-Weight → Underweight | Morgan Stanley | |
| 12/16/2022 | Neutral → Sell | Goldman |
Wells Fargo downgraded MorphoSys from Overweight to Equal Weight
Morgan Stanley downgraded MorphoSys from Overweight to Equal-Weight and set a new price target of $10.40 from $9.20 previously
Morgan Stanley upgraded MorphoSys from Underweight to Overweight and set a new price target of $9.20 from $3.70 previously
Goldman upgraded MorphoSys from Sell to Neutral and set a new price target of $9.25 from $3.50 previously
Deutsche Bank upgraded MorphoSys from Sell to Hold
JP Morgan upgraded MorphoSys from Underweight to Overweight and set a new price target of $10.00 from $3.30 previously
Wells Fargo initiated coverage of MorphoSys with a rating of Overweight and set a new price target of $17.00
UBS initiated coverage of MorphoSys with a rating of Buy
Morgan Stanley downgraded MorphoSys from Equal-Weight to Underweight
Goldman downgraded MorphoSys from Neutral to Sell
SC TO-T/A - MorphoSys AG (0001340243) (Subject)
SC 14D9/A - MorphoSys AG (0001340243) (Subject)
SC TO-T/A - MorphoSys AG (0001340243) (Subject)
6-K - MorphoSys AG (0001340243) (Filer)
SC TO-T/A - MorphoSys AG (0001340243) (Subject)
SC TO-T/A - MorphoSys AG (0001340243) (Subject)
SC TO-T/A - MorphoSys AG (0001340243) (Subject)
SC TO-T/A - MorphoSys AG (0001340243) (Subject)
SC TO-T/A - MorphoSys AG (0001340243) (Subject)
SC TO-T/A - MorphoSys AG (0001340243) (Subject)
MUNICH, GERMANY / ACCESSWIRE / August 27, 2024 / MorphoSys AG today announced that its shareholders approved all resolutions proposed by the company's Management Board and Supervisory Board at its 2024 Annual General Meeting. This included the transfer of MorphoSys' minority shareholders' shares to Novartis BidCo Germany AG (hereinafter referred to as "Novartis"), the company's majority shareholder, against a cash compensation of € 68.00 per share ("merger squeeze-out"). The merger squeeze-out will become effective once the transfer resolution and merger have been registered in the commercial register of MorphoSys, and the merger has also been registered in the commercial register of Novarti
MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares ("ADSs") from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Exchange Act of 1934 (the "Exchange Act"). MorphoSys currently anticipates that it will file with the Securities and Exchange Commission (the "SEC") a Form 25, Notification of Removal of Listing and/or Registration Under Section 12(b) of the Exchange Act, relating to the delisting and deregistration on or about July 25, 2024, with the delisting of the ADSs taking effect no earlier than ten days thereafter. As a r
MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG and Novartis AG hereinafter collectively referred to as "Novartis") also informed MorphoSys of their intention to merge MorphoSys into Novartis by initiating a squeeze-out of MorphoSys' minority shareholders. In April 2024, Novartis submitted a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares, offering MorphoSys shareholders € 68.00 per share in cash (the "T
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany AG proposed to enter negotiations with the MorphoSys AG Management Board on a merger agreement.In connection with the merger of MorphoSys AG into Novartis BidCo Germany AG, Novartis BidCo Germany AG today also submitted the formal request pursuant to section 62 para. 5 of the German Transformation Act in conjunction with section 327a para. 1 of the German Stock Corporation Act to initiate the procedur
– Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash, representing a total equity value of € 2.7 billion – Received all mandatory antitrust approvals for the proposed acquisition by Novartis – Shareholder acceptance period for the Novartis offer has commenced and will end on May 13, 2024, at 24:00 hours CEST – Sold all tafasitamab rights worldwide to Incyte – € 631.9 million in cash and other financial assets as of March 31, 2024 MorphoSys AG ((FSE: MOR, NASDAQ:MOR) reports results for the first quarter of 2024. "The proposed acquisition by Novartis is advancing steadily, and we continue to anticipate its closure in the first hal
Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billionShareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and three months before January 25, 2024, respectivelyAcceptance period has commenced and will end on May 13, 2024, at 24:00 hours CESTPLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 11, 2024 / The Management Board and Supervisory Board of MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (hereinafter collectively referred to as "Novartis"), recomm
Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion Shareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and three months before January 25, 2024, respectively Acceptance period has commenced and will end on May 13, 2024, at 24:00 hours CEST The Management Board and Supervisory Board of MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (hereinafter collectively referred to as "Novartis"), recommending that shareholders accept the offer and te
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 22, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") in connection with the proposed acquisition of MorphoSys by Novartis AG ("Novartis"), following the expiration of the HSR Act waiting period. MorphoSys previously also announced the receipt of antitrust clearance in Germany and Austria. As a result, the proposed acquisition of MorphoSys by Novartis has now received all mandatory regulatory approvals.On February 5, 2024, MorphoSys announced the intention of Novartis to submit a voluntary public takeover offer for all
– Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash or € 2.7 billion equity value – Sold all tafasitamab rights worldwide to Incyte – Presented comprehensive Phase 3 MANIFEST-2 study results at ASH 2023 Annual Meeting, demonstrating pelabresib improves all four disease hallmarks of myelofibrosis – Monjuvi® U.S. net product sales of US$ 24.1 million (€ 22.4 million) for the fourth quarter of 2023 and US$ 92.0 million (€ 85.0 million) for the full year of 2023 – € 680.5 million in cash and other financial assets as of December 31, 2023 – MorphoSys to host conference call and webcast on Thursday, March 14, 2024, at 1:00 pm CET (12:00
Conference Call AlertPLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 7, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).MorphoSys' Management team will host a conference call and webcast on March 14, 2024, at 01:00 pm CET (12:00 pm GMT; 08:00 am EDT) to present the results for the financial year 2023 and provide an outlook for 2024.The conference call will start with a presentation by the Management team followed by a Q&A session.A live webcast and slides will be made available in the Investors section of the MorphoSys' website, www.morphosys.com.To join the conference call via pho